Going deep for drug discovery: an ocean to bedside approach to explore sub-seafloor microbes for the next generation of antibiotics.
Going deep for drug discovery: an ocean to bedside approach to explore sub-seafloor microbes for the next generation of antibiotics.
复制标题
DOI：
--
复制
发表时间：
2012-09
期刊：
影响因子：
--
通讯作者：
Stephanie R. Forschner-Dancause;K. LaPlante;David C. Smith;D. Rowley
中科院分区：
文献类型：
--
作者：
Stephanie R. Forschner-Dancause;K. LaPlante;David C. Smith;D. Rowley
世界卫生组织罗德岛医药卫生组织已将抗菌素耐药性确定为对人类健康的三大威胁之一。今天，耐甲氧西林金黄色葡萄球菌(MRSA)感染在美国医院造成的死亡人数超过了结核病和艾滋病毒/艾滋病的总和。重症监护病房60%以上的葡萄球菌感染是由耐药菌株引起的，经常会遇到对多种药物缺乏敏感性的菌株。此外，越来越多的人发现致病性大肠埃希菌和肺炎克雷伯菌会产生一种广谱的酶，这大大减少了治疗感染的药物选择，而且往往给患者留下有限的甚至没有抗菌治疗的选择。令人遗憾的是，抗菌素的研发没有跟上耐药性上升的步伐。目前还没有治疗多重耐药的革兰氏阴性病原体的新药处于后期开发阶段。深入药物发现：探索海底微生物寻找下一代抗生素的海洋到床边方法
mediciNe & HealtH/RHode iSlaNd the world health organIzatIon haS identified antimicrobial resistance as one of the top three greatest threats to human health. Today, infections by methicillinresistant Staphylococcus aureus (MRSA) account for more deaths in US hospitals than both tuberculosis and HIV/AIDS combined. More than 60% of staph infections in intensive care units are due to drug resistant strains, and it is common to encounter those that lack sensitivity to multiple classes of drugs. In addition, pathogenic Escherichia coli and Klebsiella pneumoniae are increasingly found to produce an extended spectrum of enzymes that significantly decrease drug options for treating infections and often leave patients with limited to no antimicrobial treatment options. Regrettably, antimicrobial research and development is not keeping pace with rising drug resistance. There are currently no novel drugs in late stage development for the treatment of multidrug-resistant Gram-negative pathogens. Going deep for drug discovery: an ocean to Bedside Approach to Explore Sub-Seafloor Microbes for the Next Generation of antibiotics